Intrinsic Value of S&P & Nasdaq Contact Us

Zoetis Inc. ZTS NYSE

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
71/100
4/7 Pass
SharesGrow Intrinsic Value
$130.84
+8%
Analyst Price Target
$143.86
+18.8%

Zoetis Inc. (ZTS) generated $2.9B in operating cash flow for fiscal year 2025. After capital expenditures of $621M, free cash flow was $2.28B.

Free cash flow margin was 24.1% of revenue. Cash conversion ratio was 1.09x, indicating earnings are backed by cash.

The company returned $889M in dividends and $3.24B in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (76/100, Pass) — $2.28B (24.1% FCF margin) supports a durable competitive advantage
  • INCOME (85/100) — Cash conversion ratio was 1.09x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 71/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
71/100
SG Score
View full scorecard →
~
VALUE
48/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
58/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
76/100
Proven by this page
GROWTH
65/100
→ Income
INCOME
85/100
→ Income
Zoetis Inc. Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $2.9B$2.9B$2.95B$2.35B$1.91B
Capital Expenditure $-621M$-621M$-655M$-732M$-586M
Free Cash Flow $2.28B$2.28B$2.3B$1.62B$1.33B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message